Optimize Meds for Comorbidities in Nonalcoholic Fatty Liver Disease

September 2017

You'll see more patients with nonalcoholic fatty liver disease (NAFLD).

Up to 100 million Americans have this buildup of fat in the liver...usually without any symptoms. It often goes hand in hand with obesity, dyslipidemia, insulin resistance, and diabetes.

About 20% of patients with NAFLD have nonalcoholic steatohepatitis (NASH)...the more severe form with inflammation and sometimes fibrosis. It's set to be the top reason for liver transplants in the U.S. by 2020.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote